Same Drug Class

Nivolumab vs Upadacitinib

Nivolumab vs Upadacitinib: Overview

This comparison examines the pharmacological differences between Nivolumab and Upadacitinib.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

Pharmacokinetics

Half-life: Nivolumab — 27 days; Upadacitinib — 9-14 hours.

Chemical Properties

Molecular Formula: Upadacitinib — C17H19F3N6O.

Molecular Weight: Upadacitinib — 380.3700 g/mol.

Type: Nivolumab — Antibody; Upadacitinib — Small molecule.